


Abstract

The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof



wherein

the dashed line may represent a double bond;

- R is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups J selected from:
halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, -C(O)R₂, nitro, hydroxy, -NR₃R₄, cyano and or a group Z;
- R₁ is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 thioalkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C1-C6 alkoxy, halogen, NR₃R₄ or cyano;
- R₂ is a C1-C4 alkyl, -OR₃ or -NR₃R₄;
- R₃ is hydrogen or C1-C6 alkyl;
- R₄ is hydrogen or C1-C6 alkyl;
- R₅ is a C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C3-C7 cycloalkyl, hydroxy, halogen, nitro, cyano, -NR₃R₄; -C(O)R₂;
- R₆ is a C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C3-C7 cycloalkyl, hydroxy, halogen, nitro, cyano, -NR₃R₄; -C(O)R₂;
- R₇ is hydrogen, C1-C6 alkyl, halogen or halo C1-C6 alkyl;
- R₈ is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR₃R₄ or cyano;
- R₉ is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR₃R₄ or cyano;
- R₁₀ is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR₃R₄ or cyano;
- R₁₁ is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR₃R₄ or cyano;
- R₁₂ is R₃ or -C(O)R₂;
- D is CR₈R₉ or is CR₈ when double bonded with G;

- G is $CR_{10}R_{11}$ or is CR_{10} when double bonded with D or is CR_{10} when double bonded with X when X is carbon;
 X is carbon or nitrogen;
 Y is nitrogen or $-CR_7$;
 W is a 4-8 membered ring, which may be saturated or may contain one to three double bonds, and

in which:

- one carbon atom is replaced by a carbonyl or $S(O)_m$; and
- one to four carbon atoms may optionally be replaced by oxygen, nitrogen or NR_{12} , $S(O)_m$, carbonyl, and such ring may be further substituted by 1 to 8 R_6 groups;

Z is a 5-6 membered heterocycle, which may be substituted by 1 to 8 R_5 groups or a phenyl ring, which may be substituted by 1 to 4 R_5 groups;

m is an integer from 0 to 2.

to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).